READ THIS AS WELL
Press Release Source: WayPoint Biomedical Holdings, Inc.
WayPoint Biomedical Holdings Secures National Retailer for Health Essist(R) Hangover-Free Patch Product Line
Thursday September 20, 7:00 am ET
HUNTINGTON BEACH, CA--(MARKET WIRE)--Sep 20, 2007 -- WayPoint Biomedical Holdings, Inc. (Other OTC:WYPH.PK - News) is proud to announce that their Hangover-Free Patch product line has been accepted and is currently available in Love's Travel Stops and Country Stores across the USA.
ADVERTISEMENT
Love's Travel Stops is a nationally recognized leader and top retailer in the travel center business. Headquartered in Oklahoma City, Oklahoma, Love's continues to expand their travel stop network, recently opening their 200th travel stop on I-65 in Horse Cave, Kentucky.
WayPoint VP of Sales & Marketing, Phill Richer, comments, "We are delighted to have such a prestigious retailer as Love's Travel Stops selling the Hangover-Free Patch products coast-to-coast in over 30 states." WayPoint currently supplies Love's through McLane Company, Inc., a leading national Convenience Store distribution group headquartered in Temple, Texas.
About WayPoint Biomedical Holdings, Inc.:
WayPoint Biomedical Holdings, Inc. (Other OTC:WYPH.PK - News) is a pioneering biomedical firm specializing in products for enhancing human health, wellness and fitness. The Company develops and markets a unique array of cutting-edge products, including their transdermal Health Essist® Hangover-Free Topical Patch for the Retail Convenience Store market. WayPoint's unique and affordable products are focused on providing all-natural wellness enhancement solutions and relief. The Company's primary target sector is the rapidly growing Over the Counter (OTC) natural health and wellness market. For more information on the WayPoint Biomedical Holdings range of Health Essist® products visit www.patch-me-in.com.
Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.
Contact:
Investor Relations:
Steven Fox
714-848-3200
E-mail: foxrsteven@aol.com
